Renal Protection at a Metabolic Cost: A Systematic Review and Meta-Analysis of Perioperative Use of Sodium-Glucose Cotransporter 2 Inhibitors - PubMed
a day ago
- #SGLT2 inhibitors
- #perioperative care
- #renal protection
- The study examines the perioperative use of SGLT2 inhibitors, balancing risks of diabetic ketoacidosis (DKA) and euglycemic ketoacidosis (eKA) against potential renal protection benefits.
- A meta-analysis of 10 studies involving 246,242 patients found no significant association between SGLT2 inhibitor use and eKA or DKA in the primary analysis, but sensitivity analysis showed increased risks.
- SGLT2 inhibitors were associated with significant reductions in mortality (OR 0.73) and acute renal injury (OR 0.68), highlighting their renoprotective effects.
- Patients on SGLT2 inhibitors had lower perioperative pH, base excess, and blood glucose levels, indicating metabolic changes.
- The study concludes that while SGLT2 inhibitors offer significant survival and renal benefits, their use requires careful metabolic monitoring due to the latent risk of ketoacidosis.